Deep Value: cash covers more than 100% of the stock price

This company holds roughly $315M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Amarin Corporation

AMRN

Biotechnology · Healthcare

Price

$14.09

+0.03 (+0.21%)

Market Cap

$291.4M

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Mixed

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+3.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 20.1M (2021) → 20.7M (2025)

Winston Score History

The full picture

Amarin is a pharmaceutical company focused on cardiovascular health. Its main product is Vascepa (icosapentaenoic acid, or EPA), a prescription fish-oil-derived pill used to lower triglycerides and reduce the risk of heart attacks and strokes in high-risk patients. Vascepa is sold primarily in the United States, with doctors prescribing it to adults who already take cholesterol-lowering drugs but still have elevated triglyceride levels.

Amarin makes money by selling Vascepa to wholesalers and pharmacies, who then dispense it to patients with prescriptions. The company operates mainly in the US, though it has licensed Vascepa to partners in other markets like Europe and the Middle East. Its competitive position has weakened significantly because generic versions of Vascepa entered the US market after Amarin lost a key patent lawsuit, putting heavy pressure on sales and pricing. The main challenge going forward is rebuilding revenue in a market now crowded with cheaper generic alternatives.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-42.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+41.2% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$20M/ year

↓ Declining (-5% vs prior year)

9.3% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$315M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Amarin Corporation's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

35.5%

Modest — 35.5% gross margin

Profit after running costs

Operating Margin

-28.4%

Losing money on operations — -28.4%

Return on the money invested

ROCE

-7.4%

Weak — -7.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-15.1%

Shrinking sales (-15.1% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

26.4%

Converts sales into free cash efficiently (26.4%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.01

Conservative — low debt load (0.01)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial